




Arrowhead Pharmaceuticals, Inc.
Investor Relations Department
225 South Lake Avenue
Suite 1050
Pasadena, CA 91101
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARWR

Last Trade:	5.72
Trade Time:	4:00 PM ET Jan 17, 2018
Change:	0.12  (+2.143%)
Day Range	5.37 - 5.86
52-Week Range	1.42 - 6.25
Volume	1,861,201


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jan 17, 2018

[Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock](#)

Dec 27, 2017

[Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors](#)

Dec 22, 2017

[Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV](#)

Dec 20, 2017

[Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT](#)

Dec 18, 2017

[Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635\(C\)\(4\)](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Dec 12, 2017

[Annual Report \(10-K\)](#)

Feb 1, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 3, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Feb 6, 2017

[Quarterly Report \(10-Q\)](#)